Pharmacogenetic considerations in the treatment of HIV

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1 Laskey SB, Siliciano RF. A mechanistic theory to explain the efficacy of antiretroviral therapy. Nat. Rev. Microbiol. 12(11), 772–780 (2014).
  Medline CASGoogle Scholar
• 2 Pau AK, George JM. Antiretroviral therapy: current drugs. Infect. Dis. Clin. North Am. 28(3), 371–402 (2014). • Detailed description of drugs, their mechanism of action and side effects.
  MedlineGoogle Scholar
• 3 Tozzi V. Pharmacogenetics of antiretrovirals. Antiviral Res. 85(1), 190–200 (2010).
  Medline CASGoogle Scholar
• 4 Whirl-Carrillo M, McDonagh EM, Hebert JM et al. Pharmacogenomics knowledge for personalized medicine. Clin. Pharmacol. Ther. 92(4), 414–417 (2012). •• Database that gathers information about pharmacogenes, drugs, pathways and genetic variations.
  Medline CASGoogle Scholar
• 5 Günthard HF, Aberg JA, Eron JJ et al. Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel. JAMA 312(4), 410–425 (2014).
  MedlineGoogle Scholar
• 6 Günthard HF, Saag MS, Benson CA et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2016 recommendations of the International Antiviral Society-USA Panel. JAMA 316(2), 191–210 (2016).
  MedlineGoogle Scholar
• 7 World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach (2016). www.who.int/hiv/pub/arv/arv-2016/en/. • More recent guidelines for HIV infection treatment.
  Google Scholar
• 8 Bazzoli C, Jullien V, Le Tiec C, Rey E, Mentré F, Taburet AM. Intracellular pharmacokinetics of antiretroviral drugs in HIV-infected patients, and their correlation with drug action. Clin. Pharmacokinet. 49(1), 17–45 (2010).
  Medline CASGoogle Scholar
• 9 Bhatti AB, Usman M, Kandi V. Current scenario of HIV/AIDS, treatment options, and major challenges with compliance to antiretroviral therapy. Cureus 8(3), e515 (2016).
  MedlineGoogle Scholar
• 10 Clutter DS, Jordan MR, Bertagnolio S, Shafer RW. HIV-1 drug resistance and resistance testing. Infect. Genet. Evol. doi:10.1016/j.meegid.2016.08.031 (2016) (Epub ahead of print). •• Complete revision about HIV drug resistance mutations.
  MedlineGoogle Scholar
• 11 Michaud V, Bar-Magen T, Turgeon J, Flockhart D, Desta Z, Wainberg MA. The dual role of pharmacogenetics in HIV treatment: mutations and polymorphisms regulating antiretroviral drug resistance and disposition. Pharmacol. Rev. 64(3), 803–833 (2012).
  Medline CASGoogle Scholar
• 12 Hetherington S, Hughes AR, Mosteller M et al. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet 359(9312), 1121–1122 (2002).
  Medline CASGoogle Scholar
• 13 Barreiro P, Fernández-Montero JV, de Mendoza C, Labarga P, Soriano V. Pharmacogenetics of antiretroviral therapy. Expert Opin. Drug Metab. Toxicol. 10(8), 1119–1130 (2014).
  Medline CASGoogle Scholar
• 14 Asensi V, Collazos J, Valle-Garay E. Can antiretroviral therapy be tailored to each human immunodeficiency virus-infected individual? Role of pharmacogenomics. World J. Virol. 4(3), 169–177 (2015).
  MedlineGoogle Scholar
• 15 Aceti A, Gianserra L, Lambiase L, Pennica A, Teti E. Pharmacogenetics as a tool to tailor antiretroviral therapy: a review. World J. Virol. 4(3), 198–208 (2015).
  MedlineGoogle Scholar
• 16 Haas DW, Tarr PE. Perspectives on pharmacogenomics of antiretroviral medications and HIV-associated comorbidities. Curr. Opin. HIV AIDS 10(2), 116–122 (2015).
  Medline CASGoogle Scholar
• 17 Lakhman SS, Ma Q, Morse GD. Pharmacogenomics of CYP3A: considerations for HIV treatment. Pharmacogenomics 10(8), 1323–1339 (2009).
  CASGoogle Scholar
• 18 Zanger UM, Klein K. Pharmacogenetics of cytochrome P450 2B6 (CYP2B6): advances on polymorphisms, mechanisms, and clinical relevance. Front. Genet. 4, 24 (2013). • Summarizes recent advances on the functional and clinical significance of CYP2B6 and its genetic polymorphism.
  Medline CASGoogle Scholar
• 19 Thorn CF, Lamba JK, Lamba V, Klein TE, Altman RB. PharmGKB summary: very important pharmacogene information for CYP2B6. Pharmacogenet. Genomics 20(8), 520–523 (2010).
  Medline CASGoogle Scholar
• 20 Amirimani B, Ning B, Deitz AC, Weber BL, Kadlubar FF, Rebbeck TR. Increased transcriptional activity of the CYP3A4*1B promoter variant. Environ. Mol. Mutagen. 42(4), 299–305 (2003).
  Medline CASGoogle Scholar
• 21 Haas DW, Ribaudo HJ, Kim RB et al. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS 18(18), 2391–2400 (2004).
  Medline CASGoogle Scholar
• 22 Haas DW, Smeaton LM, Shafer RW et al. Pharmacogenetics of long-term responses to antiretroviral regimens containing efavirenz and/or nelfinavir: an Adult Aids Clinical Trials Group study. J. Infect. Dis. 192(11), 1931–1942 (2005).
  Medline CASGoogle Scholar
• 23 Haas DW, Bartlett JA, Andersen JW et al. Pharmacogenetics of nevirapine-associated hepatotoxicity: an Adult AIDS Clinical Trials Group collaboration. Clin. Infect. Dis. 43(6), 783–786 (2006).
  Medline CASGoogle Scholar
• 24 Ciccacci C, Borgiani P, Ceffa S et al. Nevirapine-induced hepatotoxicity and pharmacogenetics: a retrospective study in a population from Mozambique. Pharmacogenomics 11(1), 23–31 (2010).
  CASGoogle Scholar
• 25 Ciccacci C, Di Fusco D, Marazzi MC et al. Association between CYP2B6 polymorphisms and nevirapine-induced SJS/TEN: a pharmacogenetics study. Eur. J. Clin. Pharmacol. 69(11), 1909–1916 (2013).
  Medline CASGoogle Scholar
• 26 Swart M, Skelton M, Ren Y, Smith P, Takuva S, Dandara C. High predictive value of CYP2B6 SNPs for steady-state plasma efavirenz levels in South African HIV/AIDS patients. Pharmacogenet. Genomics 23(8), 415–427 (2013).
  Medline CASGoogle Scholar
• 27 Haas DW, Severe P, Jean Juste MA, Pape JW, Fitzgerald DW. Functional CYP2B6 variants and virologic response to an efavirenz-containing regimen in Port-au-Prince, Haiti. J. Antimicrob. Chemother. 69(8), 2187–2190 (2014).
  Medline CASGoogle Scholar
• 28 Sukasem C, Manosuthi W, Koomdee N et al. Low level of efavirenz in HIV-1-infected Thai adults is associated with the CYP2B6 polymorphism. Infection 42(3), 469–474 (2014).
  Medline CASGoogle Scholar
• 29 Wang D, Guo Y, Wrighton SA, Cooke GE, Sadee W. Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs. Pharmacogenomics J. 11(4), 274–286 (2011).
  MedlineGoogle Scholar
• 30 Olagunju A, Schipani A, Siccardi M et al. CYP3A4*22 (c.522–191 C>T; rs35599367) is associated with lopinavir pharmacokinetics in HIV-positive adults. Pharmacogenet. Genomics 24(9), 459–463 (2014).
  Medline CASGoogle Scholar
• 31 Swart M, Dandara C. Genetic variation in the 3′-UTR of CYP1A2, CYP2B6, CYP2D6, CYP3A4, NR1I2, and UGT2B7: potential effects on regulation by microRNA and pharmacogenomics relevance. Front. Genet. 5, 167 (2014).
  MedlineGoogle Scholar
• 32 Haas DW, Kwara A, Richardson DM et al. Secondary metabolism pathway polymorphisms and plasma efavirenz concentrations in HIV-infected adults with CYP2B6 slow metabolizer genotypes. J. Antimicrob. Chemother. 69(8), 2175–2182 (2014).
  Medline CASGoogle Scholar
• 33 Sukasem C, Chamnanphon M, Koomdee N et al. Pharmacogenetics and clinical biomarkers for subtherapeutic plasma efavirenz concentration in HIV-1 infected Thai adults. Drug Metab. Pharmacokinet. 29(4), 289–295 (2014).
  Medline CASGoogle Scholar
• 34 Zhang D, Chando TJ, Everett DW, Patten CJ, Dehal SS, Humphreys WG. In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation. Drug Metab. Dispos. 33(11), 1729–1739 (2005).
  Medline CASGoogle Scholar
• 35 Lankisch TO, Moebius U, Wehmeier M et al. Gilbert's disease and atazanavir: from phenotype to UDP-glucuronosyltransferase haplotype. Hepatology 44(5), 1324–1332 (2006).
  Medline CASGoogle Scholar
• 36 Park WB, Choe PG, Song KH et al. Genetic factors influencing severe atazanavir-associated hyperbilirubinemia in a population with low UDP-glucuronosyltransferase 1A1*28 allele frequency. Clin. Infect. Dis. 51(1), 101–106 (2010).
  Medline CASGoogle Scholar
• 37 Ferraris L, Viganò O, Peri A et al. Switching to unboosted atazanavir reduces bilirubin and triglycerides without compromising treatment efficacy in UGT1A1*28 polymorphism carriers. J. Antimicrob. Chemother. 67(9), 2236–2242 (2012).
  Medline CASGoogle Scholar
• 38 Rodríguez-Nóvoa S, Martín-Carbonero L, Barreiro P et al. Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia. AIDS 21(1), 41–46 (2007).
  Medline CASGoogle Scholar
• 39 Turatti L, Sprinz E, Lazzaretti RK et al. Short communication: UGT1A1*28 variant allele is a predictor of severe hyperbilirubinemia in HIV-infected patients on HAART in southern Brazil. AIDS Res. Hum. Retroviruses 28(9), 1015–1018 (2012).
  Medline CASGoogle Scholar
• 40 Schackman BR, Haas DW, Becker JE et al. Cost–effectiveness analysis of UGT1A1 genetic testing to inform antiretroviral prescribing in HIV disease. Antivir. Ther. 18(3), 399–408 (2013).
  MedlineGoogle Scholar
• 41 Nigam SK. What do drug transporters really do? Nat. Rev. Drug Discov. 14(1), 29–44 (2015).
  Medline CASGoogle Scholar
• 42 Rodriguez-Novoa S, Labarga P, Soriano V. Pharmacogenetics of tenofovir treatment. Pharmacogenomics 10(10), 1675–1685 (2009).
  CASGoogle Scholar
• 43 Marzocchetti A, Schwarz J, Di Giambenedetto S et al. The effect of polymorphisms in candidate genes on the long-term risk of lipodystrophy and dyslipidemia in HIV-infected white patients starting antiretroviral therapy. AIDS Res. Hum. Retroviruses 27(12), 1299–1309 (2011).
  Medline CASGoogle Scholar
• 44 Coelho AV, Silva SP, de Alencar LC et al. ABCB1 and ABCC1 variants associated with virological failure of first-line protease inhibitors antiretroviral regimens in Northeast Brazil patients. J. Clin. Pharmacol. 53(12), 1286–1293 (2013).
  Medline CASGoogle Scholar
• 45 Manosuthi W, Sukasem C, Thongyen S, Nilkamhang S, Sungkanuparph S. ABCC2*1C and plasma tenofovir concentration are correlated to decreased glomerular filtration rate in patients receiving a tenofovir-containing antiretroviral regimen. J. Antimicrob. Chemother. 69(8), 2195–2201 (2014).
  Medline CASGoogle Scholar
• 46 da Rocha IM, Gasparotto AS, Lazzaretti RK, Notti RK, Sprinz E, Mattevi VS. Polymorphisms associated with renal adverse effects of antiretroviral therapy in a Southern Brazilian HIV cohort. Pharmacogenet. Genomics 25(11), 541–547 (2015).
  Medline CASGoogle Scholar
• 47 Wanga V, Venuto C, Morse GD et al. Genomewide association study of tenofovir pharmacokinetics and creatinine clearance in AIDS Clinical Trials Group protocol A5202. Pharmacogenet. Genomics 25(9), 450–461 (2015).
  Medline CASGoogle Scholar
• 48 Rungtivasuwan K, Avihingsanon A, Thammajaruk N et al. Influence of ABCC2 and ABCC4 polymorphisms on tenofovir plasma concentrations in Thai HIV-infected patients. Antimicrob. Agents Chemother. 59(6), 3240–3245 (2015).
  Medline CASGoogle Scholar
• 49 Dahlin A, Wittwer M, de la Cruz M et al. A pharmacogenetic candidate gene study of tenofovir-associated Fanconi syndrome. Pharmacogenet. Genomics 25(2), 82–92 (2015).
  Medline CASGoogle Scholar
• 50 Pushpakom SP, Liptrott NJ, Rodríguez-Nóvoa S et al. Genetic variants of ABCC10, a novel tenofovir transporter, are associated with kidney tubular dysfunction. J. Infect. Dis. 204(1), 145–153 (2011).
  Medline CASGoogle Scholar
• 51 Liptrott NJ, Pushpakom S, Wyen C et al. Association of ABCC10 polymorphisms with nevirapine plasma concentrations in the German Competence Network for HIV/AIDS. Pharmacogenet. Genomics 22(1), 10–19 (2012).
  Medline CASGoogle Scholar
• 52 Phillips E, Bartlett JA, Sanne I et al. Associations between HLA-DRB1*0102, HLA-B*5801, and hepatotoxicity during initiation of nevirapine-containing regimens in South Africa. J. Acquir. Immune Defic. Syndr. 62(2), e55–e57 (2013).
  MedlineGoogle Scholar
• 53 Martin AM, Nolan D, James I et al. Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts. AIDS 19(1), 97–99 (2005).
  Medline CASGoogle Scholar
• 54 Littera R, Carcassi C, Masala A et al. HLA-dependent hypersensitivity to nevirapine in Sardinian HIV patients. AIDS 20(12), 1621–1626 (2006).
  Medline CASGoogle Scholar
• 55 Gatanaga H, Yazaki H, Tanuma J et al. HLA-Cw8 primarily associated with hypersensitivity to nevirapine. AIDS 21(2), 264–265 (2007).
  MedlineGoogle Scholar
• 56 Finkelstein JL, Gala P, Rochford R, Glesby MJ, Mehta S. HIV/AIDS and lipodystrophy: implications for clinical management in resource-limited settings. J. Int. AIDS Soc. 18, 19033 (2015).
  MedlineGoogle Scholar
• 57 Maher B, Alfirevic A, Vilar FJ, Wilkins EG, Park BK, Pirmohamed M. TNF-alpha promoter region gene polymorphisms in HIV-positive patients with lipodystrophy. AIDS 16(15), 2013–2018 (2002).
  Medline CASGoogle Scholar
• 58 Tarr PE, Taffé P, Bleiber G et al. Modeling the influence of APOC3, APOE, and TNF polymorphisms on the risk of antiretroviral therapy-associated lipid disorders. J. Infect. Dis. 191(9), 1419–1426 (2005).
  Medline CASGoogle Scholar
• 59 Arnedo M, Taffé P, Sahli R et al. Contribution of 20 single nucleotide polymorphisms of 13 genes to dyslipidemia associated with antiretroviral therapy. Pharmacogenet. Genomics 17(9), 755–764 (2007).
  Medline CASGoogle Scholar
• 60 Mahajan SD, Gaekwad A, Pawar J et al. Cardiac morbidity in an HIV-1 lipodystrophy patient cohort expressing the TNF-α-238 G/A single nucleotide gene polymorphism. Curr. HIV Res. 13(2), 98–108 (2015).
  Medline CASGoogle Scholar
• 61 Chang SY, Ko WS, Kao JT et al. Association of single-nucleotide polymorphism 3 and c.553G>T of APOA5 with hypertriglyceridemia after treatment with highly active antiretroviral therapy containing protease inhibitors in HIV-infected individuals in Taiwan. Clin. Infect. Dis. 48(6), 832–835 (2009).
  Medline CASGoogle Scholar
• 62 Lazzaretti RK, Gasparotto AS, Sassi MG et al. Genetic markers associated to dyslipidemia in HIV-infected individuals on HAART. ScientificWorldJournal 2013, 608415 (2013).
  MedlineGoogle Scholar
• 63 Egaña-Gorroño L, Martínez E, Cormand B, Escribà T, Gatell J, Arnedo M. Impact of genetic factors on dyslipidemia in HIV-infected patients starting antiretroviral therapy. AIDS 27(4), 529–538 (2013).
  Medline CASGoogle Scholar
• 64 Rotger M, Bayard C, Taffé P et al. Contribution of genome-wide significant single-nucleotide polymorphisms and antiretroviral therapy to dyslipidemia in HIV-infected individuals: a longitudinal study. Circ. Cardiovasc. Genet. 2(6), 621–628 (2009).
  Medline CASGoogle Scholar
• 65 Guardiola M, Echeverria P, González M et al. Polymorphisms in LPL, CETP, and HL protect HIV-infected patients from atherogenic dyslipidemia in an allele-dose-dependent manner. AIDS Res. Hum. Retroviruses 31(9), 882–888 (2015).
  Medline CASGoogle Scholar
• 66 Nadel J, Holloway CJ. Screening and risk assessment for coronary artery disease in HIV infection: an unmet need. HIV Med. doi:10.1111/hiv.12422 (2016) (Epub ahead of print).
  MedlineGoogle Scholar
• 67 Willig AL, Overton ET. Metabolic complications and glucose metabolism in HIV infection: a review of the evidence. Curr. HIV/AIDS Rep. 13(5), 289–296 (2016).
  MedlineGoogle Scholar
• 68 Hart AB, Samuels DC, Hulgan T. The other genome: a systematic review of studies of mitochondrial DNA haplogroups and outcomes of HIV infection and antiretroviral therapy. AIDS Rev. 15(4), 213–220 (2013). • Summarizes the published literature on associations between mtDNA haplogroups and clinical outcomes in populations of European and African descent.
  MedlineGoogle Scholar
• 69 Hulgan T, Stein JH, Cotter BR et al. Mitochondrial DNA variation and changes in adiponectin and endothelial function in HIV-infected adults after antiretroviral therapy initiation. AIDS Res. Hum. Retroviruses 29(10), 1293–1299 (2013).
  Medline CASGoogle Scholar
• 70 Trinca JR, Sprinz E, Lazzaretti RK et al. SNPs in the APM1 gene promoter are associated with adiponectin levels in HIV-infected individuals receiving HAART. J. Acquir. Immune Defic. Syndr. 55(3), 299–305 (2010).
  Medline CASGoogle Scholar
• 71 Castilhos JK, Sprinz E, Lazzaretti RK, Kuhmmer R, Mattevi VS. Polymorphisms in adiponectin receptor genes are associated with lipodystrophy-related phenotypes in HIV-infected patients receiving antiretroviral therapy. HIV Med. 16(8), 494–501 (2015).
  Medline CASGoogle Scholar
• 72 Brumme ZL, Dong WW, Chan KJ et al. Influence of polymorphisms within the CX3CR1 and MDR-1 genes on initial antiretroviral therapy response. AIDS 17(2), 201–208 (2003).
  Medline CASGoogle Scholar
• 73 Gasparotto AS, Sprinz E, Lazzaretti RK et al. Genetic polymorphisms in estrogen receptors and sexual dimorphism in fat redistribution in HIV-infected patients on HAART. Aids 26(1), 19–26 (2012).
  Medline CASGoogle Scholar
• 74 Chastain DB, King TS, Stover KR. Infectious and non-infectious etiologies of cardiovascular disease in human immunodeficiency virus infection. Open AIDS J. 10, 113–126 (2016).
  MedlineGoogle Scholar
• 75 Samineni D, Desai PB, Sallans L, Fichtenbaum CJ. Steady-state pharmacokinetic interactions of darunavir/ritonavir with lipid-lowering agent rosuvastatin. J. Clin. Pharmacol. 52(6), 922–931 (2012).
  Medline CASGoogle Scholar
• 76 Romaine SP, Bailey KM, Hall AS, Balmforth AJ. The influence of SLCO1B1 (OATP1B1) gene polymorphisms on response to statin therapy. Pharmacogenomics J. 10(1), 1–11 (2010).
  Medline CASGoogle Scholar
• 77 Aquilante CL, Kiser JJ, Anderson PL et al. Influence of SLCO1B1 polymorphisms on the drug–drug interaction between darunavir/ritonavir and pravastatin. J. Clin. Pharmacol. 52(11), 1725–1738 (2012).
  Medline CASGoogle Scholar
• 78 Cohen K, Grant A, Dandara C et al. Effect of rifampicin-based antitubercular therapy and the cytochrome P450 2B6 516G>T polymorphism on efavirenz concentrations in adults in South Africa. Antivir. Ther. 14(5), 687–695 (2009).
  Medline CASGoogle Scholar
• 79 Manosuthi W, Sukasem C, Lueangniyomkul A et al. Impact of pharmacogenetic markers of CYP2B6, clinical factors, and drug–drug interaction on efavirenz concentrations in HIV/tuberculosis-coinfected patients. Antimicrob. Agents Chemother. 57(2), 1019–1024 (2013).
  Medline CASGoogle Scholar
• 80 Bienvenu E, Swart M, Dandara C, Ashton M. The role of genetic polymorphisms in cytochrome P450 and effects of tuberculosis co-treatment on the predictive value of CYP2B6 SNPs and on efavirenz plasma levels in adult HIV patients. Antiviral Res. 102, 44–53 (2014).
  Medline CASGoogle Scholar
• 81 Ngaimisi E, Mugusi S, Minzi O et al. Effect of rifampicin and CYP2B6 genotype on long-term efavirenz autoinduction and plasma exposure in HIV patients with or without tuberculosis. Clin. Pharmacol. Ther. 90(3), 406–413 (2011).
  Medline CASGoogle Scholar
• 82 Lee KY, Lin SW, Sun HY et al. Therapeutic drug monitoring and pharmacogenetic study of HIV-infected ethnic Chinese receiving efavirenz-containing antiretroviral therapy with or without rifampicin-based anti-tuberculous therapy. PLoS ONE 9(2), e88497 (2014).
  MedlineGoogle Scholar
• 83 Kwara A, Lartey M, Sagoe KW, Court MH. Paradoxically elevated efavirenz concentrations in HIV/tuberculosis-coinfected patients with CYP2B6 516TT genotype on rifampin-containing antituberculous therapy. AIDS 25(3), 388–390 (2011).
  Medline CASGoogle Scholar
• 84 Bertrand J, Verstuyft C, Chou M et al. Dependence of efavirenz- and rifampicin–isoniazid-based antituberculosis treatment drug–drug interaction on CYP2B6 and NAT2 genetic polymorphisms: ANRS 12154 study in Cambodia. J. Infect. Dis. 209(3), 399–408 (2014).
  Medline CASGoogle Scholar
• 85 Chantarangsu S, Mushiroda T, Mahasirimongkol S et al. Genome-wide association study identifies variations in 6p21.3 associated with nevirapine-induced rash. Clin. Infect. Dis. 53(4), 341–348 (2011).
  Medline CASGoogle Scholar
• 86 Holzinger ER, Grady B, Ritchie MD et al. Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants. Pharmacogenet. Genomics 22(12), 858–867 (2012).
  Medline CASGoogle Scholar
• 87 Leger PD, Johnson DH, Robbins GK et al. Genome-wide association study of peripheral neuropathy with D-drug-containing regimens in AIDS Clinical Trials Group protocol 384. J. Neurovirol. 20(3), 304–308 (2014).
  Medline CASGoogle Scholar
• 88 Johnson DH, Venuto C, Ritchie MD et al. Genomewide association study of atazanavir pharmacokinetics and hyperbilirubinemia in AIDS Clinical Trials Group protocol A5202. Pharmacogenet. Genomics 24(4), 195–203 (2014).
  Medline CASGoogle Scholar
• 89 Lehmann DS, Ribaudo HJ, Daar ES et al. Genome-wide association study of virologic response with efavirenz-containing or abacavir-containing regimens in AIDS clinical trials group protocols. Pharmacogenet. Genomics 25(2), 51–59 (2015).
  Medline CASGoogle Scholar
• 90 Moore CB, Verma A, Pendergrass S et al. Phenome-wide association study relating pretreatment laboratory parameters with human genetic variants in AIDS clinical trials group protocols. Open Forum Infect. Dis. 2(1), ofu113 (2015). • Defines properties and principles of phenome-wide association studies and discusses their potential applications.
  MedlineGoogle Scholar
• 91 Schackman BR, Scott CA, Walensky RP, Losina E, Freedberg KA, Sax PE. The cost–effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV. AIDS 22(15), 2025–2033 (2008).
  MedlineGoogle Scholar
• 92 Schackman BR, Haas DW, Park SS, Li XC, Freedberg KA. Cost–effectiveness of CYP2B6 genotyping to optimize efavirenz dosing in HIV clinical practice. Pharmacogenomics 16(18), 2007–2018 (2015). •• Exemplifies cost–effectiveness studies.
  CASGoogle Scholar